<i>SQSTM1</i> mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

Elisa Rubino(University of Turin), Innocenzo Rainero, Adriano Chiò, Ekaterina Rogaeva, Daniela Galimberti, Pierpaola Fenoglio, Yakov Grinberg, Giancarlo Isaia, Andrea Calvo, S Gentile, Amalia C. Bruni, Peter St George‐Hyslop, Elio Scarpini, Salvatore Gallone(University of Turin), Lorenzo Pinessi, Innocenzo Rainero, Elisa Rubino(University of Turin), Salvatore Gallone(University of Turin), Lorenzo Pinessi, Patrizia Ferrero(Azienda Ospedaliero Universitaria San Giovanni Battista), Maria Teresa Giordana(University of Turin), Marco Di Stefano(Azienda Ospedaliero Universitaria San Giovanni Battista), Paola Martino(University of Turin), Flora Govone(University of Turin), Alessandro Vacca(University of Turin), Silvia Boschi(University of Turin), Giuseppe Marrali(University of Turin), Elisa Negro(University of Toronto), Gabriella Restagno(University of Turin), Cristina Moglia(University of Turin)
Neurology
September 13, 2012
Cited by 281Open Access
Full Text

Abstract

OBJECTIVE: There is increasing evidence that common genetic risk factors underlie frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Recently, mutations in the sequestosome 1 (SQSTM1) gene, which encodes p62 protein, have been reported in patients with ALS. P62 is a multifunctional adapter protein mainly involved in selective autophagy, oxidative stress response, and cell signaling pathways. The purpose of our study was to evaluate the frequency of SQSTM1 mutations in a dataset of unrelated patients with FTLD or ALS, in comparison with healthy controls and patients with Paget disease of bone (PDB). METHODS: Promoter region and all exons of SQSTM1 were sequenced in a large group of subjects, including patients with FTLD or ALS, healthy controls, and patients with PDB. The clinical characteristics of patients with FTLD or ALS with gene mutations were examined. RESULTS: We identified 6 missense mutations in the coding region of SQSTM1 in patients with either FTLD or ALS, none of which were found in healthy controls or patients with PDB. In silico analysis suggested a pathogenetic role for these mutations. Furthermore, 7 novel noncoding SQSTM1 variants were found in patients with FTLD and patients with ALS, including 4 variations in the promoter region. CONCLUSIONS: SQSTM1 mutations are present in patients with FTLD and patients with ALS. Additional studies are warranted in order to better investigate the role of p62 in the pathogenesis of both FTLD and ALS.


Related Papers

No related papers found

Powered by citation graph analysis